Health & Wellness Blog - Page 34

Claudia Oshry on 'Relief' Restarting GLP-1s After Pregnancy & Low-Lift Hacks

Claudia Oshry is candid about restarting GLP-1 medications after welcoming son Reuben, calling it a 'relief' that helped her stay present during pregnancy and breastfeeding. The Toast host loves low-lift wellness like water, electrolytes, sun, and Dulcolax gummies for gut health. Now embracing her postpartum body, she blocks GLP-1 criticism amid life-changing results.

Shotlee·Apr 20, 2026·6 min read

GLP-1 Medications

Is 'Ozempic Personality' Real? Mental Health Complaints Examined

Ozempic has transformed weight loss by silencing 'food noise' for many users, but now 'Ozempic personality' is sparking debate. A report highlights mental health complaints during treatment. Is this side effect real, or just hype?

Shotlee·Apr 20, 2026·5 min read

GLP-1 Medications

India Seizes 260+ Suspected Fake Mounjaro Pens, Raw Materials from Alibaba

Authorities in India have seized more than 260 suspected fake Mounjaro pens, uncovering a counterfeit operation sourcing peptides from Alibaba and selling them cheaply on IndiaMART. The primary accused lacked a pharmaceutical license and produced them at a private property. This incident underscores growing risks in the booming obesity drug market as Mounjaro becomes India's top-seller.

Shotlee·Apr 20, 2026·5 min read

Obesity Treatment Market Analysis

Beyond GLP-1Rs: Emerging Targets to Surge 50-Fold in Obesity Market

While GLP-1R agonists like semaglutide (Wegovy) and tirzepatide (Zepbound) dominate the obesity market, non-GLP-1R targets are poised for explosive growth. Sales for these alternatives are expected to surge almost 50-fold from $310m in 2026 to $15.5bn in 2031, driven by calcitonin receptor drugs. This diversification signals a reshaping of the $172.6bn obesity pharmaceutical landscape by 2031.

Shotlee·Apr 20, 2026·5 min read

Celebrity Metabolic Health

Adele's Before & After Pics Highlight 100-Pound Weight Loss

Musician Adele transformed her body in 2020, losing 100 pounds via exercise and a healthy diet amid rising anxiety after her 2019 divorce. Before Ozempic and Mounjaro gained popularity, she focused on building physical and mental strength. Her before-and-after photos and candid interviews reveal a powerful story of self-improvement.

Shotlee·Apr 20, 2026·5 min read

GLP-1 Medications

GLP-1 Slimming Drugs Boom Sparks Misuse Concerns in India

The surge in GLP-1 weight-loss injections like semaglutide in India, fueled by prices dropping up to 90%, is alarming doctors amid rising cosmetic misuse by young women. Social media and wedding pressures are pushing unsupervised use, risking serious side effects. Experts stress these are prescription therapies for obesity, not quick fixes.

Shotlee·Apr 20, 2026·5 min read

Beauty and Wellness Trends

Men Coined 'Looksmaxxing,' Women Invented It: Trends & Risks

Looksmaxxing started in incel circles but mirrors women's long history of extreme beauty pursuits, from plastic surgery to Ozempic weight loss. Radical tactics like bone-smashing and crystal meth highlight its dangers, while celebrity denials fuel uncanny reactions. Unpack the cultural shift pushing men into fraught body modification.

Shotlee·Apr 20, 2026·7 min read

GLP-1 Medications

Indian Companies Rush to Make Generic GLP-1s Like Semaglutide

India's pharma giants are in a fierce race to develop generic GLP-1 drugs like semaglutide following its patent expiry, amid soaring obesity rates affecting nearly a third of adults. One executive dubbed it a 'bloodbath' as demand surges. Eli Lilly's CEO highlighted oral pills as a key solution to global supply shortages.

Shotlee·Apr 20, 2026·4 min read

GLP-1 Medications & Market Analysis

Generic Semaglutide Share Rises to 33% in 10 Days, Boosting Torrent, Dr. Redd...

The launch of generic Semaglutide in India has rapidly captured 33% market share within just 10 days, according to CLSA's channel checks, primarily benefiting Torrent Pharmaceuticals, Dr. Reddy's Laboratories, and Zydus Lifesciences. This surge has dented Eli Lilly's Mounjaro share from 61% to 56%. As generics make GLP-1 therapies more accessible, what does this mean for patients with type 2 diabetes and obesity?

Shotlee·Apr 20, 2026·5 min read

Latest Articles

Latest Articles

Claudia Oshry on 'Relief' Restarting GLP-1s After Pregnancy & Low-Lift Hacks

Is 'Ozempic Personality' Real? Mental Health Complaints Examined

India Seizes 260+ Suspected Fake Mounjaro Pens, Raw Materials from Alibaba

Beyond GLP-1Rs: Emerging Targets to Surge 50-Fold in Obesity Market

Adele's Before & After Pics Highlight 100-Pound Weight Loss

GLP-1 Slimming Drugs Boom Sparks Misuse Concerns in India

Men Coined 'Looksmaxxing,' Women Invented It: Trends & Risks

Indian Companies Rush to Make Generic GLP-1s Like Semaglutide

Generic Semaglutide Share Rises to 33% in 10 Days, Boosting Torrent, Dr. Redd...

Latest Articles

Claudia Oshry on 'Relief' Restarting GLP-1s After Pregnancy & Low-Lift Hacks

Is 'Ozempic Personality' Real? Mental Health Complaints Examined

India Seizes 260+ Suspected Fake Mounjaro Pens, Raw Materials from Alibaba

Beyond GLP-1Rs: Emerging Targets to Surge 50-Fold in Obesity Market

Adele's Before & After Pics Highlight 100-Pound Weight Loss

GLP-1 Slimming Drugs Boom Sparks Misuse Concerns in India

Men Coined 'Looksmaxxing,' Women Invented It: Trends & Risks

Indian Companies Rush to Make Generic GLP-1s Like Semaglutide

Generic Semaglutide Share Rises to 33% in 10 Days, Boosting Torrent, Dr. Redd...